Lumateperone · Caplyta

Small molecule

Also known as ITI-007

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Schizophrenia, Bipolar Depression

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Bipolar Depression
NCT06372964 · Intra-Cellular Therapies, Inc.
2024-05-14 – 2031-10-31 · Bipolar Depression
What this study did
NCT02600494 · Intra-Cellular Therapies, Inc.
2015-12-15 – 2019-07-24 · Bipolar Depression
What this study did
Major Depressive Disorder
NCT07747389 · Intra-Cellular Therapies, Inc.
2026-11-11 – 2029-10-23 · Depressive Disorder, Major
What this study did
NCT07623135 · Eric Lenze
2026-09-01 – 2028-06 · Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
What this study did
NCT05850689 · Intra-Cellular Therapies, Inc.
2023-05-02 – 2027-04-05 · Major Depressive Disorder
What this study did
NCT04285515 · Intra-Cellular Therapies, Inc.
2020-02-27 – 2022-11-30 · Bipolar Depression, Major Depressive Disorder
What this study did
Schizophrenia
NCT06229210 · Intra-Cellular Therapies, Inc.
2024-01-25 – 2032-04-28 · Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
What this study did
NCT06482554 · Louisiana State University Health Sciences Center Shreveport
2024-06 – 2026-12 · Apathy, Schizophrenia, Schizophrenia; Psychosis
What this study did
Other / comorbidity
NCT06690398 · Intra-Cellular Therapies, Inc.
2024-11-22 – 2027-07-19 · Irritability Associated With Autism Spectrum Disorder
What this study did
NCT06706674 · Intra-Cellular Therapies, Inc.
2024-12-06 – 2027-06-21 · Irritability Associated With Autism Spectrum Disorder
What this study did
NCT06462612 · Intra-Cellular Therapies, Inc.
2024-07-17 – 2026-05-20 · Bipolar Disorder, Manic
What this study did
NCT06462586 · Intra-Cellular Therapies, Inc.
2024-06-19 – 2026-03-05 · Bipolar Disorder, Manic
What this study did
NCT02817906 · Intra-Cellular Therapies, Inc.
2016-08-29 – 2019-01-30 · Agitation in Dementia, Including Alzheimer's Disease
What this study did
Phase 2 (5)
Schizophrenia
NCT03817528 · New York State Psychiatric Institute
2019-03-01 – 2020-09-23 · Schizophrenia
What this study did
NCT02288845 · Intra-Cellular Therapies, Inc.
2014-10 – 2015-09 · Schizophrenia
What this study did
Other / comorbidity
NCT07734103 · CSTrials Inc.
2026-04-18 – 2027-10-31 · Stuttering, Adult
What this study did
NCT05356013 · University of Chicago
2023-05-10 – 2025-12-31 · Borderline Personality Disorder
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02078310 · Intra-Cellular Therapies, Inc.
2014-02 – 2014-11 · Alzheimer's Disease
What this study did
Phase 1 (3)
Schizophrenia
NCT06627413 · Intra-Cellular Therapies, Inc.
2024-08-23 – 2025-11-20 · Schizophrenia or Schizoaffective
What this study did
NCT04779177 · Intra-Cellular Therapies, Inc.
2021-03-12 – 2022-07-30 · Schizophrenia, Pediatric
What this study did
Other / comorbidity
NCT06557902 · Intra-Cellular Therapies, Inc.
2024-05-10 – 2025-11-26 · Autism Spectrum Disorder
What this study did
Phase 4 (8)
Bipolar Depression
NCT07699445 · Massachusetts General Hospital
2026-09-09 – 2028-07-31 · Bipolar Depression Depressed Phase, Obesity & Overweight
What this study did
Major Depressive Disorder
NCT07948031 · Sultan Qaboos University
2027-06 – 2030-06 · Major Depressive Disorder
What this study did
NCT07369115 · University of Texas at Austin
2026-02 – 2030-01 · Major Depressive Diorder, Early Life Trauma
What this study did
NCT07824206 · Future Options Research, LLC
2026-09 – 2028-03 · Blunted Emotion in Major Depressive Disorder
What this study did
Schizophrenia
NCT06174116 · University of Massachusetts, Worcester
2024-04-02 – 2027-03 · Schizophrenia, Schizo Affective Disorder
What this study did
Other / comorbidity
NCT07799493 · Jason Careri
2026-09-10 – 2028-05-28 · Social Anxiety Disorder (SAD)
What this study did
NCT05890768 · University of New Mexico
2023-05-11 – 2024-02-28 · Psychosis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Schizophrenia
NCT04709224 · Intra-Cellular Therapies, Inc.
2020-12-30 – 2022-05-23 · Schizophrenia
What this study did

Competitive landscape

Other Serotonin 5-HT2A / dopamine D1-D2 receptor drugs

Deulumateperone. Compare all 2 Serotonin 5-HT2A / dopamine D1-D2 receptor drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Bipolar Depression: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lumateperone (Caplyta): this drugApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
D-Cycloserine / Lurasidone (NRX-101)Phase 3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Deulumateperone
Phase 3(overall)
Small moleculeSerotonin 5-HT2A / dopamine D1-D2 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-932
Phase 1(overall)
Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Caplyta (Lumateperone) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 3SchizophreniaRecruiting
Est. primary completion 2026-12 · NCT06482554 · CT.gov ↗
What to watch
Phase 4SchizophreniaRecruiting
Est. primary completion 2026-12 · NCT06174116 · CT.gov ↗
What to watch
2027 (5)
March 2027 (1)
Phase 4Bipolar 1 DepressionNot yet recruiting
Est. primary completion 2027-03 · NCT07676669 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2027-04-05 · NCT05850689 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Irritability Associated With Autism Spectrum DisorderRecruiting
Est. primary completion 2027-06-21 · NCT06706674 · CT.gov ↗
What to watch
Phase 3Irritability Associated With Autism Spectrum DisorderRecruiting
Est. primary completion 2027-06-21 · NCT06690398 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Stuttering, AdultRecruiting
Est. primary completion 2027-07-31 · NCT07734103 · CT.gov ↗
What to watch
2028 (4)
January 2028 (2)
Phase 4Major Depressive DisorderNot yet recruiting
Est. primary completion 2028-01 · NCT07824206 · CT.gov ↗
What to watch
Phase 4Bipolar DepressionRecruiting
Est. primary completion 2028-01-31 · NCT07699445 · CT.gov ↗
What to watch
May 2028 (1)
Phase 4Social Anxiety Disorder (SAD)Recruiting
Est. primary completion 2028-05-18 · NCT07799493 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2028-06 · NCT07623135 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Phase 3Major Depressive DisorderNot yet recruiting
Est. primary completion 2029-09-20 · NCT07747389 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 4Major Depressive DisorderNot yet recruiting
Est. primary completion 2030-01 · NCT07369115 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4Major Depressive DisorderNot yet recruiting
Est. primary completion 2030-05 · NCT07948031 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3Bipolar DepressionRecruiting
Est. primary completion 2031-10-31 · NCT06372964 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 3SchizophreniaRecruiting
Est. primary completion 2032-04-28 · NCT06229210 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 September 2026Topline resultStudy 451 phase 3 topline
Johnson & Johnson · Source ↗
27 April 2026ApprovalFDA approves CAPLYTA sNDA for relapse prevention in schizophrenia
US, FDA · Source ↗
6 November 2025ApprovalFDA approves CAPLYTA for adjunctive treatment of MDD
US, FDA · Source ↗
5 November 2025ApprovalFDA Boxed Warning on Caplyta (NDA209500)
US, FDA · FDA · Source ↗
8 July 2025Filing submittedJohnson & Johnson submits a CAPLYTA sNDA for schizophrenia relapse prevention
US, FDA · Johnson & Johnson · Source ↗